Literature DB >> 19821538

Increased vulnerability of the spinal cord to radiation or intrathecal chemotherapy during adolescence: A report from the Children's Oncology Group.

Archie Bleyer1, Mehee Choi, Samuel J Wang, Clifton D Fuller, R Beverly Raney.   

Abstract

PURPOSE: To assess the rate of spinal cord toxicity in adolescents resulting from chemoradiotherapy of parameningeal sarcoma. METHODS AND MATERIALS: Of 152 patients with parameningeal sarcoma treated per the Intergroup Rhabdomyosarcoma Study Group protocol from 1977 through 1989, eight developed paralyzing ascending myelitis after intrathecal chemotherapy with cytosine arabinoside, methotrexate, and hydrocortisone administered during and after radiation therapy to volumes that included part of the spinal cord. The eight cases include three not previously published.
RESULTS: Of eight patients who developed CNS toxicity after intrathecal chemotherapy and radiotherapy for parameningeal rhabdomyosarcoma, all but one were between 13 and 18 years of age when treated. This severe toxicity occurred in one quarter of 28 adolescents treated with the regimen in comparison with one of 123 children 12 years of age or less (P < 0.0001), a rate that was as much as 30 times higher in the adolescents. Lengthening of the spinal cord during the pubertal growth spurt may account for the apparent increased vulnerability.
CONCLUSIONS: Chemoradiotoxicity-associated spinal cord injury appears to be more likely to occur in adolescents than in younger or older ages. This observation appears to reverse a conventional wisdom in which the central nervous system is thought to become more resistant to the neurotoxic effects of chemoradiotherapy as it matures. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19821538     DOI: 10.1002/pbc.22164

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  6 in total

1.  Neuropathic pain referrals to a multidisciplinary pediatric cancer pain service.

Authors:  Doralina L Anghelescu; Lane G Faughnan; Mark P Popenhagen; Linda L Oakes; Deqing Pei; Laura L Burgoyne
Journal:  Pain Manag Nurs       Date:  2012-08-25       Impact factor: 1.929

2.  Radiation Myelopathy Caused by Palliative Radiotherapy and Intrathecal Methotrexate.

Authors:  Yukiko Fukuda; Satoru Takahashi; Michiko Nakamura; Masashi Endo; Kazunari Ogawa; Masahiro Kawahara; Keiko Akahane; Shoko Ito; Yoshinobu Kanda; Harushi Mori; Katsuyuki Shirai
Journal:  Case Rep Oncol       Date:  2022-07-01

3.  Young Adult Populations Face Yet Another Barrier to Care With Insurers: Limited Access to Proton Therapy.

Authors:  Andrew J Bishop; J Andrew Livingston; Matt S Ning; Isaac D Valdez; Cody A Wages; Mary Fran McAleer; Arnold C Paulino; David R Grosshans; Kristina D Woodhouse; Randa Tao; Michael E Roth; G Brandon Gunn; Susan L McGovern
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-03-04       Impact factor: 8.013

Review 4.  Relapsed Medulloblastoma in Pre-Irradiated Patients: Current Practice for Diagnostics and Treatment.

Authors:  Rebecca M Hill; Sabine L A Plasschaert; Beate Timmermann; Christelle Dufour; Kristian Aquilina; Shivaram Avula; Laura Donovan; Maarten Lequin; Torsten Pietsch; Ulrich Thomale; Stephan Tippelt; Pieter Wesseling; Stefan Rutkowski; Steven C Clifford; Stefan M Pfister; Simon Bailey; Gudrun Fleischhack
Journal:  Cancers (Basel)       Date:  2021-12-28       Impact factor: 6.575

5.  Subacute quadriplegic myelopathy following intrathecal methotrexate.

Authors:  Boby Varkey Maramattom; Sandeep Padmanabhan; Vivek Radhakrishnan
Journal:  Indian J Med Paediatr Oncol       Date:  2016 Jul-Sep

Review 6.  Transverse myelitis.

Authors:  Shin C Beh; Benjamin M Greenberg; Teresa Frohman; Elliot M Frohman
Journal:  Neurol Clin       Date:  2013-02       Impact factor: 3.806

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.